Yingzhong Li
President & Chief Executive Officer SunVax mRNA Therapeutics
Yingzhong Li earned his Ph.D. on Biotechnology from Peking University & National Institute of Biological Sciences, Beijing, China in 2010. Dr. Li got further trainings on multiple disciplines and interdisciplinary at MIT. Currently Dr. Li holds 6 PCT patents at MIT and 5 PCT patents at SunVax mRNA Therapeutics in the field of cancer immunology and mRNA techniques. Dr. Li is President of SunVax mRNA Therapeutics Inc. after left MIT in the end of 2021.
Seminars
Tuesday 29th September 2026
Panel Discussion: Advancing Purification Strategies for Circular & Self-Amplifying RNA to Improve Purity, Boost Yield, & Enable Scalable, Regulatory-Ready Manufacturing
2:30 pm
Key questions include:
- Are current circRNA purification strategies fundamentally overcomplicated – and where can we simplify without compromising quality?
- How do you balance purity, yield, and scalability when designing purification processes for clinical and commercial manufacturing?
- What will define a “fit-for-purpose” purification platform for circRNA as the field moves toward first-in-human and beyond?
Wednesday 30th September 2026
Overcoming CMC & Operational Challenges to Enable Successful saRNA Development
10:30 am
- Navigating key manufacturing challenges in saRNA development, including scalability, process robustness, and product quality considerations
- Evaluating and selecting the right CRO partners to support efficient development, tech transfer, and long-term program success
- Applying effective cross-functional project management strategies to streamline timelines, communication, and CMC execution across saRNA programs
